Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|11|2|77-87

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.11, Iss.2, 2016-08, pp. : 77-87

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

By Steuer Conor E.   Ramalingam Suresh S.  

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2392-2402

Blackwell Publishing

Access to resources Recommend Favorite

Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer

By  

Current Drug Discovery Technologies, Vol. 6, Iss. 2, 2009-06 ,pp. : 91-102

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapies for Non-Small Cell Lung Cancer

By  

Current Pharmaceutical Design, Vol. 13, Iss. 27, 2007-09 ,pp. : 2810-2831

Bentham Science Publishers

Access to resources Recommend Favorite

Crizotinib: In Locally Advanced or Metastatic Non-Small Cell Lung Cancer

By Curran Monique P.  

Drugs, Vol. 72, Iss. 1, 2012-01 ,pp. : 99-107

Adis International

Access to resources Recommend Favorite

The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 67-73

Bentham Science Publishers

Access to resources Recommend Favorite